Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity
Bonn, S., Herrero, S., Breitenlechner, C.B., Erlbruch, A., Lehmann, W., Engh, R.A., Gassel, M., Bossemeyer, D.(2006) J Biol Chem 281: 24818-24830
- PubMed: 16699172 
- DOI: 10.1074/jbc.M512374200
- Primary Citation of Related Structures:  
2GFC, 2GNF, 2GNG, 2GNH, 2GNI, 2GNJ, 2GNL - PubMed Abstract: 
Controlling aberrant kinase-mediated cellular signaling is a major strategy in cancer therapy; successful protein kinase inhibitors such as Tarceva and Gleevec verify this approach. Specificity of inhibitors for the targeted kinase(s), however, is a crucial factor for therapeutic success ...